X

Trial Profile

A proof-of-concept Investigator-Initiated Trial of NGGT002 for the treatment of Phenylketonuria (PKU) in humans.

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NGGT 002 (Primary)
Indications Phenylketonuria
Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

14 Nov 2024 According to the Next Generation Gene Therapeutics Media Release, data demonstrate the safety and efficacy of NGGT002 for the treatment of PKU presented at the National PKU Alliance biennial conference in July.
14 Nov 2024 New trial record
11 Nov 2024 Results present in the Next Generation Gene Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com